Characterising methamphetamine use to inform health and social policies in Manitoba, Canada: a protocol for a retrospective cohort study using linked administrative data

被引:5
作者
Nickel, Nathan C. [1 ,2 ]
Enns, Jennifer E. [3 ]
Freier, Amy [3 ]
McCulloch, Scott C. [3 ]
Chartier, Mariette [3 ]
Casidsid, Hera J. M. [3 ]
Balogun, Oludolapo Deborah [3 ]
Mulhall, Drew [4 ]
Dragan, Roxana [3 ]
Sarkar, Joykrishna [3 ]
Bolton, James [5 ]
Konrad, Geoffrey [5 ]
Phillips-Beck, Wanda [6 ]
Sanguins, Julianne [7 ]
Shimmin, Carolyn [8 ]
McDonald, Neil [9 ]
Mignone, Javier [1 ]
Hinds, Aynslie [1 ]
机构
[1] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada
[2] Manitoba Inuit Assoc, Winnipeg, MB, Canada
[3] Univ Manitoba, Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada
[4] Univ Manitoba, Dept Orthoped Surg, Winnipeg, MB, Canada
[5] Univ Manitoba, Dept Psychiat, Winnipeg, MB, Canada
[6] First Nations Hlth & Social Secretariat Manitoba, Winnipeg, MB, Canada
[7] Manitoba Metis Federat, Winnipeg, MB, Canada
[8] George & Fay Yee Ctr Healthcare Innovat, Winnipeg, MB, Canada
[9] Winnipeg Fire Paramed Serv, Winnipeg, MB, Canada
来源
BMJ OPEN | 2022年 / 12卷 / 10期
关键词
epidemiology; mental health; substance misuse; OPIOID OVERDOSE; MENTAL-HEALTH; PHARMACOTHERAPY; DEPENDENCE; MORTALITY; DEATH; AMPHETAMINE; MANAGEMENT; INDIVIDUALS; POPULATION;
D O I
10.1136/bmjopen-2022-062127
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Rising use of methamphetamine is causing significant public health concern in Canada. The biological and behavioural effects of methamphetamine range from wakefulness, vigour and euphoria to adverse physical health outcomes like myocardial infarction, haemorrhagic stroke, arrhythmia and seizure. It can also cause severe psychological complications such as psychosis. National survey data point to increasing rates of methamphetamine use, as well as increasing ease of access and serious methamphetamine-related harms. There is an urgent need for evidence to address knowledge gaps, provide direction to harm reduction and treatment efforts and inform health and social policies for people using methamphetamine. This protocol describes a study that aims to address this need for evidence. Methods The study will use linked, whole population, de-identified administrative data from the Manitoba Population Research Data Repository. The cohort will include individuals in the city of Winnipeg, Manitoba, who came into contact with the health system for reasons related to methamphetamine use from 2013 to 2021 and a comparison group matched on age, sex and geography. We will describe the cohort's sociodemographic characteristics, calculate incidence and prevalence of mental disorders associated with methamphetamine use and examine rates of health and social service use. We will evaluate the use of olanzapine pharmacotherapy in reducing adverse emergency department outcomes. In partnership with Indigenous co-investigators, outcomes will be stratified by First Nations and Metis identity. Ethics and dissemination The study was approved by the University of Manitoba Health Research Ethics Board, and access datasets have been granted by all data providers. We also received approval from the First Nations Health and Social Secretariat of Manitoba's Health Information Research Governance Committee and the Manitoba Metis Federation. Dissemination will be guided by an 'Evidence 2 Action' group of public rightsholders, service providers and knowledge users who will ensure that the analyses address the critical issues.
引用
收藏
页数:11
相关论文
共 67 条
  • [1] Adlaf E., 2007, CANADIAN ADDICTIONS
  • [2] Mortality and causes of death among people who inject amphetamine: A long-term follow-up cohort study from a needle exchange program in Sweden
    Ahman, Ada
    Jerkeman, Anna
    Blome, Marianne Alanko
    Bjorkman, Per
    Hakansson, Anders
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2018, 188 : 274 - 280
  • [3] Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada
    Ali, Farihah
    Russell, Cayley
    Nafeh, Frishta
    Rehm, Jurgen
    LeBlanc, Sean
    Elton-Marshall, Tara
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 93
  • [4] [Anonymous], 2010, MANITOBA 1 NATIONS S
  • [5] [Anonymous], 2018, CBC News
  • [6] A systematic review of risk factors for methamphetamine-associated psychosis
    Arunogiri, Shalini
    Foulds, James A.
    McKetin, Rebecca
    Lubman, Dan I.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 (06) : 514 - 529
  • [7] Non-pharmacological interventions for methamphetamine use disorder: a systematic review
    AshaRani, P., V
    Hombali, Aditi
    Seow, Esmond
    Ong, Wei Jie
    Tan, Jit Hui
    Subramaniam, Mythily
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2020, 212
  • [8] Bombay A, 2009, INT J INDIG HEALTH, V5, P6
  • [9] Pharmacotherapy management of schizophrenia for family physicians
    Bool, Japheth
    Crawley, Alex
    Wanson, Annabelle
    Davis, Breanna
    Halpape, Katelyn
    [J]. CANADIAN FAMILY PHYSICIAN, 2021, 67 (05) : 350 - 354
  • [10] Pharmacotherapy of amphetamine-type stimulant dependence: An update
    Brensilver, Matthew
    Heinzerling, Keith G.
    Shoptaw, Steven
    [J]. DRUG AND ALCOHOL REVIEW, 2013, 32 (05) : 449 - 460